Filing Flows › Accendra Health (ACH) › Q2 2026 › vs Q2 2025
Accendra Health (ACH) Q2 2026 vs Q2 2025 (year over year)
Accendra Health's revenue fell $68.7M (-10%) from $682M in Q2 2025 to $613M in Q2 2026. The biggest changes: Sleep therapy −$33.0M (-18%); Other −$24.6M (-34%); Home respiratory therapy −$18.5M (-17%).
Accendra Health, Q2 2026: revenue $613M (-10% year over year), operating margin -5.7%, net loss $89.1M, operating cash flow −$26.0M. The chart draws each line against Q2 2025, the increases inside each band.
Every line
| Line | Q2 2026 | Q2 2025 | Change | % |
|---|---|---|---|---|
| Diabetes | $199M | $191M | $7.8M | +4% |
| Sleep therapy | $149M | $182M | −$33.0M | -18% |
| Home respiratory therapy | $91.0M | $110M | −$18.5M | -17% |
| Ostomy | $55.7M | $51.9M | $3.8M | +7% |
| Other | $47.7M | $72.3M | −$24.6M | -34% |
| Wound care | $40.2M | $46.8M | −$6.6M | -14% |
| Urology | $31.3M | $28.7M | $2.6M | +9% |
| Revenue | $613M | $682M | −$68.7M | -10% |
| Net loss | $89.1M | $869M | −$780M | -90% |
| Costs & expenses | $702M | $1.6B | −$850M | -55% |
| Operating costs | $648M | $722M | −$73.2M | -10% |
| Interest & other, net | $52.5M | $830M | −$778M | -94% |
| Income tax | $1.4M | −$1.1M | $2.6M | — |
| Cost of revenue | $350M | $357M | −$7.5M | -2% |
| SG&A | $244M | $268M | −$24.3M | -9% |
| Other operating costs | $55.0M | $96.5M | −$41.5M | -43% |
| Operating cash sources | $95.7M | $10.2M | $85.5M | +834% |
| Depreciation & amortization | $65.7M | $43.0M | $22.7M | +53% |
| Share-based compensation | $4.0M | $4.9M | −$868K | -18% |
| Cash used in operations | $26.0M | −$37.6M | $63.6M | — |
| Net loss absorbed | $89.1M | $869M | −$780M | -90% |
| Working capital & other | $6.6M | −$859M | $865M | — |
Questions
How much did Accendra Health's revenue grow year over year in Q2 2026?
Accendra Health's revenue fell $68.7M (-10%) from $682M in Q2 2025 to $613M in Q2 2026.
What drove Accendra Health's revenue change in Q2 2026?
Sleep therapy −$33.0M (-18%); Other −$24.6M (-34%); Home respiratory therapy −$18.5M (-17%).